Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from VISEN Pharmaceuticals ( (HK:2561) ).
VISEN Pharmaceuticals has announced an amendment to its Commercial Supply Framework Agreement with Ascendis Europe, allowing a broader range of entities within the Ascendis Group to supply products. This amendment aims to optimize internal resource allocation and provide greater flexibility for both VISEN and Ascendis, enhancing their collaborative efforts.
More about VISEN Pharmaceuticals
VISEN Pharmaceuticals is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company is involved in the production and distribution of drug packages, auto-injectors, and ancillary products, primarily targeting markets in collaboration with partners like Ascendis Europe.
Average Trading Volume: 55,698
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.2B
See more data about 2561 stock on TipRanks’ Stock Analysis page.